Digest Réseau Comment ça marche
Réseau
/
Sociétés
Ac
Non vérifié

Accord Healthcare

Ce que nous écrivons

BiologieÉconomieIndustrie pharmaceutiqueSanté PubliqueStart-up

8 communiqués de presse

Voir tous les communiqués de presse
02/04/2025
Industrie pharmaceutique
Santé Publique
Accord Healthcare Receives Positive CHMP Opinion for Denosumab, Osvyrti®, and Jubereq®
Source
Accord Healthcare
Émetteur
PR News Wire
1.00
0
06/02/2025
Industrie pharmaceutique
Santé Publique
Biologie
Accord Healthcare: Hetronifly® (Serplulimab) receives Marketing Authorisation from the European Commission (EC), for the treatment of Extensive-Stage Small Cell Lung Cancer (ES- SCLC)
Source
Accord Healthcare
Émetteur
PR News Wire
1.00
0
Press Release cover image
31/01/2025
Industrie pharmaceutique
Santé Publique
Économie
Start-up
Accord Healthcare launches Disulfiram in the United Kingdom, indicated as a supportive agent in the treatment of alcoholism
Source
Accord Healthcare
Émetteur
PR News Wire
1.00
0
Press Release cover image
16/12/2024
Industrie pharmaceutique
Santé Publique
Biologie
Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®
Source
Accord Healthcare
Émetteur
PR News Wire
1.00
0
01/11/2024
Industrie pharmaceutique
Santé Publique
Entreprises
Organisation d'Entreprise
Accord Healthcare unlocks £50m government fund to boost medicines manufacturing in the North-East
Source
Accord Healthcare
Émetteur
PR News Wire
1.00
0
19/10/2024
Industrie pharmaceutique
Santé Publique
Biologie
Accord Healthcare receives positive CHMP opinion for IMULDOSA®, a ustekinumab biosimilar to Stelara®
Source
Accord Healthcare
Émetteur
PR News Wire
1.00
0
21/09/2024
Industrie pharmaceutique
Santé Publique
Économie
Start-up
Biologie
Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY® (approved as HANSIZHUANG in China) in European markets as First-Line Treatment for adult patients with Extensive-Stage Small Cell Lung Cancer
Source
Accord Healthcare
Émetteur
PR News Wire
1.00
0
14/08/2024
Industrie pharmaceutique
Santé Publique
Économie
Start-up
NICE recommends ORGOVYX® (relugolix) as the first oral ADT treatment for hormone sensitive prostate cancer in England
Source
Accord Healthcare
Émetteur
PR News Wire
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0